Hong Kong Auto Stock News

SEHK:3388
SEHK:3388Tech

Assessing Shenzhen Creality 3D Technology (SEHK:3388) Valuation After Recent Share Price Weakness

Recent share price move puts Shenzhen Creality 3D Technology in focus A sharp one day move has put Shenzhen Creality 3D Technology (SEHK:3388) on investors’ radar, with the stock falling about 9% in the latest session and roughly 8% year to date. With a market value of about HK$9.8b and reported revenue of CN¥3,127.04m against a net loss of CN¥182.561m, the company sits at an interesting point for investors assessing growth potential versus current profitability. See our latest analysis for...
SEHK:2269
SEHK:2269Life Sciences

Assessing WuXi Biologics (SEHK:2269) Valuation After Its Recent Share Price Momentum Shift

Recent share performance and company snapshot WuXi Biologics (Cayman) (SEHK:2269) has seen mixed share performance recently, with the stock edging up about 1% over the past day but declining around 10% over the past 3 months. The company runs an end to end biologics contract research, development, and manufacturing business, serving clients across North America, Europe, the People’s Republic of China, and other regions. It reported revenue of CN¥21,790.018 million and net income of...
SEHK:6990
SEHK:6990Biotechs

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) Is Down 14.8% After ASCO NSCLC Data Spotlight - Has The Bull Case Changed?

At the 2026 ASCO Annual Meeting, Sichuan Kelun-Biotech Biopharmaceutical reported past Phase III and Phase II data in NSCLC, including sacituzumab tirumotecan plus pembrolizumab showing longer progression-free survival than pembrolizumab alone and lunbotinib fumarate delivering high response rates in RET fusion-positive disease, alongside encouraging first-in-human results for its B7-H3 ADC SKB500. The inclusion of sacituzumab tirumotecan data in The Lancet and the acceptance of lunbotinib’s...
SEHK:1952
SEHK:1952Biotechs

Everest Medicines (SEHK:1952) Valuation Check After Recent Share Price Weakness

Everest Medicines Stock Moves After Recent Performance Metrics Everest Medicines (SEHK:1952) has drawn fresh attention as investors review recent share performance and financial metrics, with the stock down 1% over the past day and 4.6% over the past week. See our latest analysis for Everest Medicines. That 1 day and 7 day share price weakness comes on top of a 30 day share price return of down 14.8% and a year to date decline of 24.1%. The 3 year total shareholder return of about 1.7x the...
SEHK:1211
SEHK:1211Auto

BYD Takes On Driver Risk While Advancing Toward Solid State Batteries

BYD (SEHK:1211) has said it will assume liability for its advanced driver-assistance system, signaling a higher level of accountability for its technology. The company has also outlined plans to introduce solid-state batteries by 2027, targeting the next generation of electric vehicle battery performance. BYD shares last closed at HK$89.7, with the stock down 32.5% over the past year and still positive over 3 and 5 years, up 10.5% and 29.5% respectively. Against that backdrop, the company...
SEHK:1919
SEHK:1919Shipping

Assessing COSCO SHIPPING Holdings (SEHK:1919) Valuation After Dividend Approval And Leadership Changes

Leadership and dividend moves reshaping the picture for COSCO SHIPPING Holdings COSCO SHIPPING Holdings (SEHK:1919) has just combined a fresh round of leadership appointments with approval of its 2025 final dividend, a pairing that gives investors new information on both governance and cash returns. See our latest analysis for COSCO SHIPPING Holdings. The share price reaction has been strong around these announcements, with a 1-day share price return of 6.68% and a 7-day share price return of...
SEHK:9999
SEHK:9999Entertainment

Assessing NetEase (SEHK:9999) Valuation After Recent Share Price Weakness And Ongoing Global Expansion

Recent share performance and business snapshot NetEase (SEHK:9999) has drawn investor attention after recent share price moves, with the stock down 2.3% on the day and 1 day weakness extending through the past week. Over the past month the stock is up 3.8%, while performance over the past 3 months is roughly flat, showing a 0.4% decline. Year to date, the share price is down 17.7%, and the 1 year total return shows a 3% decline. Over longer periods, NetEase has delivered a 39.1% total return...